Cell surface tumor endothelial markers are conserved in mice and humans.

We recently identified genes encoding tumor endothelial markers (TEMs) that displayed elevated expression during tumor angiogenesis. From both biological and clinical points of view, TEMs associated with the cell surface membrane are of particular interest. Accordingly, we have further characterized four such genes, TEM1, TEM5, TEM7, and TEM8, all of which contain putative transmembrane domains. TEM5 appears to be a seven-pass transmembrane receptor, whereas TEM1, TEM7, and TEM8 span the membrane once. We identified mouse counterparts of each of these genes, designated mTEM1, mTEM5, mTEM7, and mTEM8. Examination of these mTEMs in mouse tumors, embryos, and adult tissues demonstrated that three of them (mTEM1, mTEM5, and mTEM8) were abundantly expressed in tumor vessels as well as in the vasculature of the developing embryo. Importantly, expression of these mTEMs in normal adult mouse tissues was either undetectable or detected only in a small fraction of the vessels. These results demonstrate conservation of human and mouse tumor angiogenesis at the molecular level and support the idea that tumor angiogenesis largely reflects normal physiological neovasculaturization. The coordinate expression of TEM1, TEM5, and TEM8 on tumor endothelium in humans and mice makes these genes attractive targets for the development of antiangiogenic therapies.

[1]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[2]  M. Yaffe,et al.  A motif-based profile scanning approach for genome-wide prediction of signaling pathways , 2001, Nature Biotechnology.

[3]  F. Eisenhaber,et al.  Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium* , 2001, The Journal of Biological Chemistry.

[4]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[5]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[6]  D J Ruiter,et al.  Anti‐angiogenic treatment of human cancer: Pitfalls and promises , 2000, International journal of cancer.

[7]  R. Kerbel.  Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[8]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[9]  Yasuyuki Shima,et al.  Flamingo, a Seven-Pass Transmembrane Cadherin, Regulates Planar Cell Polarity under the Control of Frizzled , 1999, Cell.

[10]  Y. Rao,et al.  The mouse SLIT family: secreted ligands for ROBO expressed in patterns that suggest a role in morphogenesis and axon guidance. , 1999, Developmental biology.

[11]  D. Staunton,et al.  The Leukocyte Integrin αDβ2 Binds VCAM-1: Evidence for a Binding Interface Between I Domain and VCAM-1 , 1999, The Journal of Immunology.

[12]  D. Staunton,et al.  The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence for a binding interface between I domain and VCAM-1. , 1999, Journal of immunology.

[13]  Thomas Gudermann,et al.  Structural basis of G protein-coupled receptor function , 1999, Molecular and Cellular Endocrinology.

[14]  A. R. Little,et al.  A Novel Ubiquitously Expressed α-Latrotoxin Receptor Is a Member of the CIRL Family of G-protein-coupled Receptors* , 1999, The Journal of Biological Chemistry.

[15]  R. Holz,et al.  Structural requirements for alpha-latrotoxin binding and alpha-latrotoxin-stimulated secretion. A study with calcium-independent receptor of alpha-latrotoxin (CIRL) deletion mutants. , 1999, The Journal of biological chemistry.

[16]  R. Holz,et al.  Structural Requirements for α-Latrotoxin Binding and α-Latrotoxin-stimulated Secretion , 1999, The Journal of Biological Chemistry.

[17]  T. Südhof,et al.  alpha-Latrotoxin receptor CIRL/latrophilin 1 (CL1) defines an unusual family of ubiquitous G-protein-linked receptors. G-protein coupling not required for triggering exocytosis. , 1998, The Journal of biological chemistry.

[18]  J. Chambers,et al.  Orphan G‐protein‐coupled receptors: the next generation of drug targets? , 1998, British journal of pharmacology.

[19]  N. Nomura,et al.  Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. , 1998, Genomics.

[20]  S. Santoro,et al.  Ligand recognition by the I domain-containing integrins , 1998, Cellular and Molecular Life Sciences CMLS.

[21]  J Schultz,et al.  SMART, a simple modular architecture research tool: identification of signaling domains. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Risau.  Angiogenesis is coming of age. , 1998, Circulation research.

[23]  S. Shaw,et al.  Thy-1, a novel marker for angiogenesis upregulated by inflammatory cytokines. , 1998, Circulation research.

[24]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[25]  鈴木 豊.  cDNA Cloning of a Novel Membrane Glycoprotein That Is Expressed Specifically in Glial Cells in the Mouse Brain LIG-1, A PROTEIN WITH LEUCINE-RICH REPEATS AND IMMUNOGLOBULIN-LIKE DOMAINS , 1998 .

[26]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[27]  P. Little,et al.  Celsr1, a neural-specific gene encoding an unusual seven-pass transmembrane receptor, maps to mouse chromosome 15 and human chromosome 22qter. , 1997, Genomics.

[28]  A Elofsson,et al.  Prediction of transmembrane alpha-helices in prokaryotic membrane proteins: the dense alignment surface method. , 1997, Protein engineering.

[29]  L. Cantley,et al.  Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains , 1997, Science.

[30]  A. Couvineau,et al.  Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP‐1, and Other Members of Their New Family of G Protein‐Linked Receptors: Structure‐Function Relationship with Special Reference to the Human VIP‐1 Receptor a , 1996, Annals of the New York Academy of Sciences.

[31]  R. Liddington,et al.  Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18) , 1995, Cell.

[32]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[33]  J. Healey,et al.  Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Bonaldo,et al.  The superfamily of proteins with von Willebrand factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms. , 1991, Blood.

[35]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[36]  J. H. Scarffe,et al.  Cancer Medicine , 1982, British Journal of Cancer.

[37]  S. Brunak,et al.  SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .

[38]  P. Little,et al.  Celsr 1 , a Neural-Specific Gene Encoding an Unusual Seven-Pass Transmembrane Receptor , Maps to Mouse Chromosome 15 and Human Chromosome 22 qter , 1997 .